Erlotinib Study for Myelodysplastic Syndrome (MDS)

Summary

The purpose of this research study is to find out what effects, good and/or bad, erlotinib has on the patient and their myelodysplastic syndrome. Erlotinib has been approved by the Food and Drug Administration (FDA) to treat non-small cell lung cancer; however, erlotinib use in this study is considered investigational as the FDA has not approved it for the treatment of myelodysplastic syndrome.

Timeline

Start

2009-09

Primary completion

2012-06

Completion

2012-06

Drugs

Indications